Search results for "Small Cell"
showing 10 items of 212 documents
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.
2009
Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.
Genetic Algorithm Optimized Grid-based RF Fingerprint Positioning in Heterogeneous Small Cell Networks
2015
In this paper we propose a novel optimization algorithm for grid-based RF fingerprinting to improve user equipment (UE) positioning accuracy. For this purpose we have used Multi-objective Genetic Algorithm (MOGA) which enables autonomous calibration of gridcell layout (GCL) for better UE positioning as compared to that of the conventional fingerprinting approach. Performance evaluations were carried out using two different training data-sets consisting of Minimization of Drive Testing measurements obtained from a dynamic system simulation in a heterogeneous LTE small cell environment. The robustness of the proposed method has been tested analyzing positioning results from two different area…
Molecular profiling and function of exosomes derived from Non-Small Cell Lung Cancer. Diagnostic, predictive and prognostic biomarkers.
2019
Abstract: abstract not available
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associat…
2017
Adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC) is a severe disease. Patients carrying EGFR mutations may benefit from EGFR targeted therapies (e.g.: gefitinib). Recently, it has been shown that sialidase NEU3 directly interacts and regulates EGFR. In this work, we investigate the effect of sialidase NEU3 overexpression on EGFR pathways activation and EGFR targeted therapies sensitivity, in a series of lung cancer cell lines. NEU3 overexpression, forced after transfection, does not affect NSCLC cell viability. We demonstrate that NEU3 overexpression stimulates the ERK pathway but this activation is completely abolished by gefitinib treatment. The Akt pathway is also hyper-activated upo…
In the literature: March 2016
2016
The way clones resistant to anti-EGFR (Epidermal Growth Factor Receptor) inhibition evolve in non-small cell lung cancer is far from being determined. In an international cooperative effort led by investigators at Johns Hopkins Hospital in Baltimore, the origin of acquired resistance mediated by the EGFRT790M mutation has been further elucidated. That mutation, recognised as gatekeeper and present in about 60% of pretreated cases with anti-EGFRs, could occur either from the selection of previously existing EGFR790M cell clones or by the evolution of originally EGFR790M-negative drug-tolerant cells. In a series of elegant experiments, the authors show that these drug-tolerant cells have a di…
Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC) : standards actuels et perspectives
2019
Resume La chirurgie est le traitement de reference des CNPC de stades I, II et IIIA. Plusieurs essais randomises de phase III de chimiotherapie adjuvante ou neoadjuvante avec une chimiotherapie a base de platine ont ete menes dans les cancers de stades I, II et IIIA. Ces essais ont demontre un gain de survie significatif de la chimiotherapie adjuvante ou neoadjuvante evalue a 5 % a 5 ans dans les stades II et IIIA. Ce benefice a ete confirme par deux meta-analyses sur donnees individuelles. En revanche pour les stades I, le benefice de la chimiotherapie n’est que suggere dans les stades IB > 4 cm. La place de la radiotherapie adjuvante dans les tumeurs N2, sera precisee par l’essai Lung-ART…
EGFR tyrosine kinase inhibitor therapy continuation with high-dose hypofractionated radiotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) p…
2020
e21580 Background: EGFR tyrosine kinase inhibitors (TKIs) represent the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, despite initial marked responses, tumors invariably develop acquired resistance to TKIs. Oligoprogression is commonly observed during treatment with oncogene-directed therapies, including EGFR TKIs, and refers to patients who experience disease progression only in limited sites as a result of heterogeneous mechanisms of resistance. The use of local ablative treatments for these resistant lesions may extend the duration of TKI therapy and potentially improve long-term disease control and survival…
A Facile Synthesis of Deaza-Analogues of the Bisindole Marine Alkaloid Topsentin
2013
A series of substituted ethyl 1-[(tert-butoxycarbonyl)amino]-2-methyl-5- (1-methyl-1H-indol-3-yl)-4-[(1-methyl-1H-indol-3-yl)carbonyl]-1H-pyrrole-3-carboxylates were prepared in excellent yields (82-98%) by one-pot reactions between β-dicarbonyl compounds 12a-e and 1,2-diaza-1,3-diene (DD) 13. Derivatives 10a,c-e, deazaanalogues of the bis-indole alkaloid topsentin, screened by the National Cancer Institute (Bethesda, MD, USA) in the in vitro one dose primary anticancer assay against a panel of about 60 human tumor cell lines, showed no significant activity, with the exception of compound 9e, which showed moderate activity against the HOP-92 cell line of the non small cell lung cancer sub-p…
Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
2019
Background Vaccine adjuvants are compounds that significantly enhance/prolong the immune response to a co-administered antigen. The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene saponin purified from Quillaja saponaria. Purpose The aim of this review is to attempt to clarify the mechanism of action of QS-21 through either receptors or signaling pathways in vitro and in vivo with special emphasis on the co-administration with other immunostimulants in new adjuvant formulations, called a…